表紙
市場調査レポート

Vernalis plcの製品パイプライン分析

Vernalis Plc - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 214139
出版日 ページ情報 英文 39 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
Vernalis plcの製品パイプライン分析 Vernalis Plc - Product Pipeline Review - 2015
出版日: 2015年12月23日 ページ情報: 英文 39 Pages
概要

Vernalis plcは開発段階の医薬品企業で、様々な疾患の治療用医薬品を開発しています。

当レポートでは、Vernalis plcにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Vernalis plcの基本情報

Vernalis plcの概要

  • 主要情報
  • 企業情報

Vernalis plc:R&Dの概要

  • 主な治療範囲

Vernalis plc:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

Vernalis plc:パイプライン製品の概況

  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 創薬中の製品/併用療法モダリティ

Vernalis plc:薬剤プロファイル

  • V-158866
  • V-81444

Vernalis plc:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Vernalis plc:最近のパイプライン動向

Vernalis plc:休止中のプロジェクト

Vernalis plc:開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
  • alphadolone
  • BB-2827
  • indantadol
  • marimastat
  • solimastat
  • V-1003
  • V-10153
  • V-24343
  • VML-670

Vernalis plc:企業発表

Vernalis plc:本社と子会社の所在地

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07930CDB

Summary

Global Markets Direct's, 'Vernalis plc - Product Pipeline Review - 2015', provides an overview of the Vernalis plc's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Vernalis plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Vernalis plc including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Vernalis plc's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Vernalis plc's pipeline products

Reasons to buy

  • Evaluate Vernalis plc's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Vernalis plc in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Vernalis plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Vernalis plc and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Vernalis plc
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Vernalis plc and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Vernalis Plc Snapshot
    • Vernalis Plc Overview
    • Key Information
    • Key Facts
  • Vernalis Plc - Research and Development Overview
    • Key Therapeutic Areas
  • Vernalis Plc - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Vernalis Plc - Pipeline Products Glance
    • Vernalis Plc - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Vernalis Plc - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
    • Vernalis Plc - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Vernalis Plc - Drug Profiles
    • V-81444
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CCP-05
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CCP-06
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • V-158411
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vipadenant
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Chk1 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CCP-07
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CCP-08
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Vernalis Plc - Pipeline Analysis
    • Vernalis Plc - Pipeline Products by Target
    • Vernalis Plc - Pipeline Products by Route of Administration
    • Vernalis Plc - Pipeline Products by Molecule Type
    • Vernalis Plc - Pipeline Products by Mechanism of Action
  • Vernalis Plc - Recent Pipeline Updates
  • Vernalis Plc - Dormant Projects
  • Vernalis Plc - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • alfadolone
      • indantadol
      • marimastat
      • solimastat
      • V-1003
      • V-158866
      • vipadenant
  • Vernalis Plc - Company Statement
  • Vernalis Plc - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Vernalis Plc, Key Information
  • Vernalis Plc, Key Facts
  • Vernalis Plc - Pipeline by Indication, 2015
  • Vernalis Plc - Pipeline by Stage of Development, 2015
  • Vernalis Plc - Monotherapy Products in Pipeline, 2015
  • Vernalis Plc - Partnered Products in Pipeline, 2015
  • Vernalis Plc - Partnered Products/ Combination Treatment Modalities, 2015
  • Vernalis Plc - Out-Licensed Products in Pipeline, 2015
  • Vernalis Plc - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Vernalis Plc - Phase II, 2015
  • Vernalis Plc - Preclinical, 2015
  • Vernalis Plc - Discovery, 2015
  • Vernalis Plc - Unknown, 2015
  • Vernalis Plc - Pipeline by Target, 2015
  • Vernalis Plc - Pipeline by Route of Administration, 2015
  • Vernalis Plc - Pipeline by Molecule Type, 2015
  • Vernalis Plc - Pipeline Products by Mechanism of Action, 2015
  • Vernalis Plc - Recent Pipeline Updates, 2015
  • Vernalis Plc - Dormant Developmental Projects,2015
  • Vernalis Plc - Discontinued Pipeline Products, 2015
  • Vernalis Plc, Subsidiaries

List of Figures

  • Vernalis Plc - Pipeline by Top 10 Indication, 2015
  • Vernalis Plc - Pipeline by Stage of Development, 2015
  • Vernalis Plc - Monotherapy Products in Pipeline, 2015
  • Vernalis Plc - Partnered Products in Pipeline, 2015
  • Vernalis Plc - Out-Licensed Products in Pipeline, 2015
  • Vernalis Plc - Pipeline by Top 10 Target, 2015
  • Vernalis Plc - Pipeline by Top 10 Route of Administration, 2015
  • Vernalis Plc - Pipeline by Top 10 Molecule Type, 2015
  • Vernalis Plc - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top